Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110437 | 1.00 | MEN1 (0.45) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL13921741 | 0.86 | MEN1 (0.47) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL9917820 | 0.83 | NPSR1 (0.40) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL30087363 | 0.82 | L3MBTL1 (0.43) | MEN1KMT2ANPSR1SRCL3MBTL1 | |
| SCHEMBL18831779 | 0.82 | ANPEP (0.40) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL31355239 | 0.81 | MMP9 (0.45) | MEN1KMT2ANPSR1SRCL3MBTL1 | |
| SCHEMBL23044634 | 0.80 | MEN1 (0.43) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL461026 | 0.80 | ANPEP (0.44) | MEN1KMT2ANPSR1SRCANPEP | |
| SCHEMBL13986909 | 0.80 | MEN1 (0.43) | MEN1KMT2ANPSR1SRCKDM4E | |
| SCHEMBL20773105 | 0.80 | ANPEP (0.44) | MEN1KMT2ANPSR1SRCANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118776-A1 | NUCLEOSIDE PHOSPHORAMIDATES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS AND PREPARATION THEREOF | QUIMICA SINTETICA S.A. (ES) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118776-A1 | NUCLEOSIDE PHOSPHORAMIDATES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS AND PREPARATION THEREOF | MTAP, PNP, UMPS | MEN1 4264/4885KMT2A 3881/4885NPSR1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.